SEC Form 5 · accession 0000899243-19-003318
Crinetics Pharmaceuticals, Inc. · CRNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alan Seth Krasner
Officer — Chief Medical Officer
Period of report
Dec 31, 2018
Accepted (ET)
Feb 12, 2019 · 5:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001658247
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 20, 2018 | J | 1,470 | $14.45 | A | 3,470 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).